Brentuximab-vedotin, anti-CD30 antibody with MMAE, was approved in 2011 for the therapy of relapsed or chemotherapy refractory (R/R) Hodgkin and anaplastic large cell lymphoma (ALCL), the two lymphoma subtypes characterized by aberrant expression of CD30 antigen [21,22]. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.